$22.32
+0.31%Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Last Annual Value
136.66M
3-Year CAGR
6%
5-Year CAGR
28%
10-Year CAGR
29%
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Pacira BioSciences, Inc. NASDAQ:PCRX | 136.66M | -0.7% | 11.3% | 31.6% | |
![]() Phathom Pharmaceuticals, Inc. NASDAQ:PHAT | -166.78M | N/A | N/A | N/A | |
![]() Tandem Diabetes Care, Inc. NASDAQ:TNDM | -29.67M | N/A | N/A | N/A | |
![]() AnaptysBio, Inc. NASDAQ:ANAB | 19.61M | N/A | N/A | N/A | |
![]() Kodiak Sciences Inc. NASDAQ:KOD | -136.51M | N/A | N/A | N/A | |
![]() Xencor, Inc. NASDAQ:XNCR | -138.27M | N/A | N/A | N/A | |
![]() UroGen Pharma Ltd. NASDAQ:URGN | -162.73M | N/A | N/A | N/A | |
![]() BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT | -114.50M | N/A | N/A | N/A |
Continue your PCRX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.